ADAPTOGENICS HEALT
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 709
- Market Cap
- $684.2M
- Introduction
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Clinical Trials
8
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
ImmuneSense™ IBD Study
- Conditions
- Inflammatory Bowel Diseases
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 484
- Registration Number
- NCT05769829
- Locations
- 🇺🇸
Hope Clinic & Research Center LLC, Hialeah, Florida, United States
🇺🇸Gold Coast Health Research Center, LLC, Miami, Florida, United States
🇺🇸Sanitas Research, Miami, Florida, United States
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Conditions
- Follicular LymphomaDiffuse Large B Cell LymphomaMantle Cell Lymphoma
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 300
- Registration Number
- NCT05255354
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
ImmuneSense™ COVID-19 Cross-Reactivity Study
- Conditions
- SARS-CoV-2 InfectionCoronavirus Disease
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Adaptive Biotechnologies
- Registration Number
- NCT05112874
- Locations
- 🇺🇸
Adaptive Biotechnologies, Seattle, Washington, United States
ImmuneSense COVID-19 Variant Study
- Conditions
- Covid19
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 203
- Registration Number
- NCT05054088
- Locations
- 🇺🇸
Decentralized Trial Model- Phoenix, Phoenix, Arizona, United States
🇺🇸Decentralized Trial Model- Fullerton, Fullerton, California, United States
🇺🇸Decentralized Trial Model- California, San Diego, California, United States
ImmuneSense™ COVID-19 Study
- Conditions
- Coronavirus Disease (COVID-19)SARS-CoV-2 Infection
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 180
- Registration Number
- NCT04583982
- Locations
- 🇺🇸
Adaptive Biotechnologies Clinical Investigational Site, Secaucus, New Jersey, United States
- Prev
- 1
- 2
- Next
News
Adaptive Biotechnologies Integrates clonoSEQ MRD Testing into Flatiron Health's OncoEMR Platform
Adaptive Biotechnologies and Flatiron Health have integrated the FDA-cleared clonoSEQ test for minimal residual disease assessment into OncoEMR, providing over 4,500 clinicians across 1,000 community cancer care locations streamlined access to MRD testing.
Adaptive Biotechnologies Enhances clonoSEQ Assay for DLBCL Minimal Residual Disease Detection with 7-Fold Sensitivity Increase
Adaptive Biotechnologies has launched an upgraded clonoSEQ assay for DLBCL that delivers a 7-fold increase in sensitivity while maintaining high specificity for detecting minimal residual disease.
Adaptive Biotechnologies Reports Strong MRD Business Growth in 2024 Financial Results
Adaptive Biotechnologies reported 42% growth in its Minimal Residual Disease (MRD) business for 2024, with clonoSEQ test volume increasing 35% to 76,105 tests delivered throughout the year.
clonoSEQ Data Show MRD Assessment Impacts Blood Cancer Treatment Decisions
Data from the ECOG-ACRIN EA4151 trial suggests auto-HCT may not benefit MCL patients in first complete remission with undetectable MRD.
Medicare Expands Coverage of Adaptive Biotechnologies' clonoSEQ for Mantle Cell Lymphoma
Palmetto GBA, a Medicare Administrative Contractor, has broadened coverage of Adaptive Biotechnologies' clonoSEQ to include measurable residual disease (MRD) detection in mantle cell lymphoma (MCL) patients.
Telo Genomics Evaluates MRD Assay in Multiple Myeloma with TELO-DMRD Study
Telo Genomics is assessing its minimal residual disease (MRD) biomarker assay technologies in multiple myeloma (MM) patients as part of the TELO-DMRD clinical validation study.
Advancements in Minimal Residual Disease Assessment Transforming Myeloma Treatment
Novel agents have shifted myeloma treatment, enabling minimal residual disease (MRD) negativity across the disease spectrum, improving patient outcomes.